Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapy candidates for the treatment of neurological disorders, today announced the successful completion of a $120 million financing. Proceeds from the financing will be used to advance the company’s pipeline of wholly-owned, off-the-shelf cell therapies for multiple indications, including its lead investigational candidate, NRTX-1001. NRTX-1001 is being evaluated in an ongoing open-label, single-arm Phase I/II clinical trial for the treatment of drug-resistant mesial temporal lobe epilepsy (MTLE) and has potential application in Alzheimer’s disease and other disorders of the nervous system.
Congratulations to UCSF Professors, Neurona co-founders and scientific advisory board members, John Rubenstein, Arturo Alvarez-Buylla, Arnold Kriegstein, and co-founder/CEO Cory Nicholas. Together, they were the UCSF researchers whose discoveries led to the company’s foundation. They, with Scott Baraban, are inventors on patents licensed to Neurona.
